Keywords: genmab, humax-cd20, enters, pivotal, ph, iii, trial

Genmab's HuMax-CD20 enters pivotal Ph III trial

Article | 05 June 2006

Copenhagen, Denmark-based drugmaker Genmab AS has initiated a Phase III pivotal study with its anticancer drug candidate HuMax-CD20 (ofatumumab) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Alemtuzumab

Campath

Fludara

Fludarabine

Go to drug listing